Abstract
Background/aims: The aim of the study was to determine the virological, serological, and histological outcome, including cccDNA, in chronic Hepatitis B (CH-B) patients after 48 weeks of pegylated interferon (PEG-IFNalpha2b) and adefovir (ADV) combination therapy (year-1-data): Hepatology2006;44:675–684), followed by 96 weeks of ADV mono therapy. Here we report the final analysis of the study after 144 weeks of antiviral treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
